Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Visit Radcliffe Cardiology:

Dr Gurleen Kaur (Brigham and Women's Hospital, US) joins us in this collaboration between @CardioNerds and Radcliffe Cardiology to interview OCEAN(a)'s primary investigator, Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) on the late-breaking data revealed at AHA.

OCEAN(a) was a dose-finding study that aimed to evaluate an siRNA, olpasiran's effect administered subcutaneously compared with placebo. Presented first at AHA 22, OCEAN(a) showed that, dosed 75 mg or higher every 12 weeks, olpasiran reduces Lp(a) concentration by more than 95% in patients with atherosclerotic cardiovascular disease. The phase 2 study demonstrated that the treatment appears to be safe and well-tolerated.

Recorded remotely from Boston, 2022.
This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA" передвинте ползунок вправо